---
schema_version: "secwatch.filing_event.v1"
accession: "0001662774-25-000034"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:08:01.526298+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics shareholders approve reverse stock split and authorized share increase

## Summary
- Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).
- Authorized common shares increased from 100M to 250M (27,159,134 for vs 3,776,348 against).
- Directors June Bray, Christopher Senner, and Rajiv Patni elected with >85% of votes cast.
- BDO USA ratified as independent auditor for FY2025 (30,015,571 for).
- Advisory vote on executive compensation passed (16,590,485 for, 800,094 against).

## SEC filing metadata
- accession: 0001662774-25-000034
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000034/0001662774-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000034/qncx-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001662774-25-000034
- JSON: https://secwatch.observer/filing/0001662774-25-000034.json
- Plain text: https://secwatch.observer/filing/0001662774-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.